Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1233P is a pseudogene of the U6 small nuclear RNA gene, part of a family of non-coding RNAs that play a central role in the splicing of pre-mRNA by assembling into the spliceosome complex[1][3][4][5]. U6 snRNA is highly conserved and essential for eukaryotic gene expression, but pseudogenes such as RNU6-1233P are formed through retrotransposon-mediated genomic duplication and mutation, resulting in genetic elements that resemble the original gene but lack functional activity[4]. These pseudogenes may serve as evolutionary markers for retrotransposon activity but are not biologically active and do not act as therapeutic targets or disease biomarkers[4][5].
None (not a druggable target, does not have a mechanism of action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1233, pseudogene (RNU6-1233P).